MED LIFE S.A.
Registered Office: Bucharest, 365, Calea Grivitei, 1st district, Romania
Unique Registration Code at the National Office of Trade Registry: 8422035
Order number on the Trade Registry: J1996003709402
Subscribed and paid-in share capital: 132,870,492 RON

SISTEMUL MEDICAL MedLife

No. 89 / 14 November 2025

To: BUCHAREST STOCK EXCHANGE
FINANCIAL SUPERVISORY AUTHORITY

ANNOUNCEMENT

Report Date: **14 November 2025**
Name of the issuing company: **MED LIFE S.A. ("MedLife" or "the Company")**
Registered Office: **Bucharest, 365 Calea Grivitei, district 1, Romania**
Telephone / Fax number: **0374 180 470**
Unique Registration Code at the National Office of Trade Registry: **8422035**
Order number on the Trade Registry: **J1996003709402**
EUID: **ROONRC.J1996003709402**
Subscribed and paid-in share capital: **RON 132,870,492**
Total number of shares: **531,481,968 (out of which 665,983 shares without voting rights and 530,815,985 shares with voting rights)**
Regulated market on which the issued securities are traded: **Bucharest Stock Exchange, Premium Category**

MedLife reports an increase of almost 20% in the first nine months compared to last year: "Genetics and AI integration open up new horizons, and MedLife will be there - not just as an user of innovation, but as a generator of medical progress"

- *In the first nine months of the year, MedLife recorded a pro-forma consolidated turnover of over RON 2.36 billion, up 19.5% compared to the same period of 2024.*
- *Hospitals remain the main vector of acceleration, registering a robust growth at the level of the 9-month period. The medical and financial performance in this business segment have led MedLife to the leading position at national level.*
- *The Group accelerates the development of genetic testing, AI integration and medical research projects, strengthening its status as a technology company that innovates and changes paradigms in the development of the healthcare market in Romania, but also in the region.*

Bucharest, November 14, 2025: MedLife, the largest private medical services network in Romania and the only company with Romanian capital among the top private healthcare operators, announces the financial results for the first nine months of 2025. The Group recorded a pro-forma consolidated turnover of over RON 2.36 billion, up 19.5% compared to the same period of 2024. Also, pro-forma EBITDA registered an important advance, standing 20.4% above the level reported in the first nine months of last year.

The evolution confirms the consolidation of the Group's leadership position and the sustainable performance of all business lines, in an economic context characterized by a moderate growth rate. The most important advances were recorded on the divisions of hospitals (+39.2%) and clinics (+19.2%), followed by laboratories (+16.1%) and pharmacies (+11.2%). The performance of these divisions confirms the positive impact of recent investments in state-of-the-art medical equipment, integrated digital solutions and strategic partnerships with leading specialists.

Accelerating innovation: genetics and artificial intelligence

In parallel with strengthening its financial performance, the company accelerates the strategic direction of development in the field of personalized medicine, by launching Longevity100+, the first and largest genetic testing program in the region. The initiative aims to democratize access to genetic testing, shifting the focus from treating advanced diseases to early risk identification and prevention. According to MedLife representatives, starting next year, the genetic testing within the program will be available to the general public, at an affordable price, marking a concrete step towards the transformation of preventive medicine in Romania.

At the same time, the Group has accelerated the development and implementation of its own AI-based solutions aimed at supporting the advanced analysis of medical images and data. These projects contribute to increasing the accuracy of the diagnosis, the safety of the medical act and the reduction of the response time for patients.

"*The results of the first nine months confirm that our growth model is solid and sustainable, even in a more moderate economic environment. The investments we make in technology, automation, genetics and artificial intelligence are not just expenses, but strategic assets that will generate value in the coming years.*

The data we report today reflects the transformation we are building: we are moving from screening and treatment medical services to personalized health plans, based on accurate data provided by genetics, state-of-the-art technology and the expertise of our multidisciplinary medical teams – a model that differentiates us in the long term and strengthens our competitive advantage" said Mihai Marcu, President and CEO of MedLife Group.

Sustained organic development

At the same time, MedLife Group continued to expand the medical infrastructure nationwide through a series of organic projects that were completed during this period.

Thus, in the hospital division, the Group marked the inauguration of the new operating block of MedLife Craiova Hospital, an investment that brings state-of-the-art technology and top surgical standards to patients in Oltenia. In the clinics division, MedLife scored an investment of over 3 million euros in Pitesti by opening a new large medical unit designed to offer integrated services - from consultations and lab tests, to imaging and day hospitalization. Also, in the laboratory division, the company inaugurated the first fully automated laboratory in Brasov, an investment of over 2 million euros, which contributes to increasing processing capacity, reducing tests analysis times and higher accuracy of results.

Applied research and innovation in medical imaging

Looking ahead, the company wants to accelerate projects based on the research component and actively contribute to improving the medical act and the patient experience. A defining project in this regard is the recently launched pilot research initiative in medical imaging, in which MedLife radiologists work side by side with an AI algorithm trained to recognize subtle patterns and contribute to the writing of standardized, complete and accurate imaging reports that will aim to increase the level of accuracy in establishing the diagnosis. With a base of nearly one million MRI investigations, this project positions Romania at the forefront of private medical research in the region, demonstrating how technology can amplify human expertise without replacing it.

"*Artificial intelligence and innovative solutions are opening up new horizons, and MedLife will be there – not just as an user of innovation, but as a generator of medical progress, capable of creating real value for patients, the community and the entire healthcare system*", concluded Mihai Marcu, President and CEO of the Group.

Through such initiatives, MedLife consolidates its status as a leader in medical innovation in Romania and its role as a driver of transformation of the health system, through constant investments in research, digitalization and the formation of elite interdisciplinary teams

Analysis of the Consolidated Comprehensive Income

Sales for the 9 months period ended September 30, 2025, amounted to RON 2,361,915,728 higher by 19.4% compared to sales recorded for the 9 months period ended September 30, 2024. This increase was mainly the result of growth in almost all of the Group's business lines, as well as the impact of the acquisitions completed by the Group in 2024 and 2025.

Operating expenses include variable and fixed costs, as well as the cost of goods and materials used to provide the Group's services. The Group recorded operating expenses of RON 2,248,786,583 for the 9 months period ended September 30, 2025, representing an increase of 20.2%, or RON 377,236,659 as compared to the similar period of 2024. The Group's operating expenses as a percentage of total operating income represented 94.83% for the 9 months period ended September 30, 2025 and 94.31% for the 9 months period 2024.

Operating profit increased by 8.6% for the 9-month period of 2025 compared to the same period of 2024, from RON 112,927,259 in 2024 to RON 122,692,182 in 2025.

Financial losses increased by RON 34,866,317 in the 9-month period of 2025, from a loss of RON 75,048,815 as of September 30, 2024 to a loss of RON 109,915,132 as of September 30, 2025, as a result of the increase in the exchange rate from December 31, 2024, 4.9741 RON for 1 EUR, to that of September 30, 2025 of 5.0811 RON for 1 EUR and the revaluation of the syndicated loan which is denominated in EUR.

The net result recorded for the 9-month period ended September 30, 2025 represents a loss of RON 6,396,903 compared to the corresponding period of 2024, representing a profit of RON 20,828,157, mainly due to currency fluctuations.

Analysis of the Consolidated Balance Sheet

Non-current assets amount to RON 2,437,309,022 as of September 30, 2025, registering an increase of RON 79,900,625, or 3.4%, compared to December 31, 2024. The increase was mainly due to the acquisition of tangible assets during the period by approximately RON 57 million.

Current assets increased by RON 46,636,892, or 7.1%, from RON 658,905,448 as of December 31, 2024 to RON 705,542,340 as of September 30, 2025.

Current liabilities (excluding interest-bearing items) decreased by RON 58,836,812, or 8%, from RON 711,442,119 as of December 31, 2024 to RON 652,605,307 as of September 30, 2025.

Interest-bearing debt increased by RON 206,723,577, or 12%, from RON 1,685,881,346 as of December 31, 2024 to RON 1,892,604,923 on September 30, 2025.

Operational Key Performance Indicators

Business line	**Info**	**9 months ended**	
		2025	**2024**
Clinics	**Revenue**	**884,149,472**	**741,702,586**
	Visits	3,615,877	3,181,076
	Avg fee	244.5	233.2
Stomatology	**Revenue**	**92,396,013**	**95,033,275**
	Visits	134,884	142,476
	Avg fee	685.0	667.0
Hospitals	**Revenue**	**652,570,668**	**468,675,295**
	Patients	155,580	117,878
	Avg fee	4,194.4	3,975.9
Laboratories	**Revenue**	**262,226,843**	**225,891,790**
	Analyses	7,994,477	6,613,519
	Avg fee	32.8	34.2
Corporate	**Revenue**	**225,999,696**	**224,533,480**
	Subscriptions	900,837	885,435
	Avg fee	250.9	253.6
Pharmacies	**Revenue**	**56,034,730**	**50,395,133**
	Clients	325,141	344,051
	Sales per client	172.3	146.5
Others	**Revenue**	**188,538,306**	**172,437,148**
Total		**2,361,915,728**	**1,978,668,707**

Report availability

The Q3 2025 results report is available on the company's website, in the Investor Relations section / Reports and Presentations / Financial Reports (https://www.medlife.ro/investor-relations/reports-and-presentations/financial-reports) and on the Bucharest Stock Exchange's website (symbol **M**).

Results presentation conference call

We remind you that MedLife will hold a conference call for analysts and investors to present the financial results, on 14 November 2025, starting 4:00 p.m. (Romanian time). The conference call will be held in English, and the related presentation and transcript will be available afterwards, on MedLife's website, in the Investor Relations section / Reports and Presentations / Financial Reports. In order to participate to the event, please contact us at investors@medlife.ro.

____
Mihail Marcu
Chief Executive Officer